• Title/Summary/Keyword: tumor-to-tumor 전이

Search Result 1,287, Processing Time 0.025 seconds

Mouse Tumor Necrosis Using Photodynamic Therapy (광역학적 치료법을 이용한 쥐의 악성종양 괴사)

  • 임현수;변상현
    • Journal of Biomedical Engineering Research
    • /
    • v.25 no.1
    • /
    • pp.49-55
    • /
    • 2004
  • In this paper, we investigated the effects of the photodynamic therapy(PDT) for the tumor mass in mice. In the experimental method, we divided the mice into two control and test group which HepG2 and HeLa cell line induced cancer mass in mice. Photofrin was administered to the tumor-bearing mouse, followed 30 hours later by 630nm and 650nm laser light exposure. After photodynamic therapy we analyzed the two mice group for the tumor mass size, tumor growth, tumor cell necrosis, pathological anatomy change. According to the results, tumor cell necrosis was shown in the tissues which the reduce size of tumor and tumor cell necrotic change according to the irradiation time and light dose amount. The considerable difference, however, between the 630nm and 650nm wavelength was not found for the tumor cell necrotic change and other damage of normal tissue was not found.

Tumor Prosthetic Replacement for the Metastatic Bone Tumors Involving the Proximal Femur (대퇴골 근위부 전이성 종양 환자의 종양 대치물 삽입술)

  • Sung, Ki-Sun;Chang, Moon-Jong
    • The Journal of the Korean bone and joint tumor society
    • /
    • v.13 no.1
    • /
    • pp.48-54
    • /
    • 2007
  • Purpose: To evaluate clinical results of the tumor prosthetic replacement for pathologic fracture of the proximal femur with extensive bony destruction due to metastatic bone tumors. Materials and Methods: From 2005 October to 2006 October, resection of proximal femur and tumor prosthesis replacement was performed for metastatic bone tumors extensively involving trochanteric area in 6 patients. The mean age of overall patients was 61(range, 48~77). Mean clinical follow up was 10.5 months (range, 6~16). Primary tumor consisted with multiple myeloma in 2 patients, lung cancer in 1, breast cancer in 1, transitional cell carcinoma of the renal pelvis in 1, unknown origin in 1 patient. $MUTARS^{(R)}$ proximal femur (Implantcast, Munster, Germany) were used in all cases. The functional evaluation in the lower extremities was performed with Musculoskeletal Tumor Society 1993 scores. The degree of pain relief after surgical treatment was assessed with Visual Analogue Scale (VAS). Results: At the final follow up, all of the patients survived. The mean lower extremities functional score of Musculoskeletal Tumor Society 1993 was 17.8(59.3%)(range, 12~25). VAS was improved to 2.5 from 8.5 after the surgical treatment. Ambulation was encouraged as soon as possible and mean duration after surgery for ambulation was 7.3(range, 3~16) days. Post-operatively, there was no surgical infection, periprosthetic fracture or loosening. Dislocation occurred in one out of six cases. Conclusion: Resection of proximal femur and tumor prosthesis replacement for metastatic bone tumors around proximal femur extensively involving trochanteric area seems to be safe procedure in view of post-operative complication, and effective for functional restoration as well as pain relief. Thus, it is accordant to the treatment principle of the metastatic bone tumors.

  • PDF

Alveolar Soft Part Sarcoma - Two Cases Report - (포상 연부 육종 - 2례 보고 -)

  • Jung, Sung-Taek;Seo, Hyoung-Yeon;Shin, Sang-Gyoo;Park, Yong-Cheol
    • The Journal of the Korean bone and joint tumor society
    • /
    • v.9 no.2
    • /
    • pp.223-232
    • /
    • 2003
  • As we know, alveolar soft part sarcoma is usually found at the head region in children and thigh in adults. It is very rare tumor that has poor prognosis due to its late detection after distant metastasis in spite of its slow growth rate. It is histologically characterized by pseudoalveolar pattern tumor cells. And metastasis usually occur in the site of lung, brain and skeleton in order lately. We have managed two cases of the sarcoma, one which took place in relatively rare part, pelvic bone and has spread to the brain, the other which primarily occured in the calf. For its varity, we report these two cases with reviewing of the literatures.

  • PDF

Gomisin A Inhibits Tumor Growth and Metastasis through Suppression of Angiogenesis (Gomisin A의 신혈관형성 저해를 통한 종양 성장 및 전이 억제 효과)

  • Kim, Do-Yoon;Yu, Ho-Jin;Yoon, Mi-So;Park, Joo-Hoon;Jang, Sang-Hee;Lee, Hwan-Myung
    • Journal of Life Science
    • /
    • v.22 no.9
    • /
    • pp.1224-1230
    • /
    • 2012
  • Cancer chemotherapy drugs command a large share of the market, and the development of new therapeutics with high efficacy and specificity is an active area of study. Recently, the development of cancer therapeutics from natural products targeting angiogenesis has drawn attention due to conventional chemotherapeutics showing serious side effects and resistance in cancer cells. In this study, we investigated the pharmacological efficacy of Gomisin A, an active ingredient of Schizandra chinensis baillon, on tumor growth and metastasis. Administration of Gomisin A at 10 and 100 ${\mu}g/ml$ reduced tumor growth in vivo by $80.5{\pm}8.1%$ and $96.2{\pm}2%$, respectively, compared with positive tumor controls. Treatment of Gomisin A in normal and various tumor cell lines did not exert significant toxicity. Mice treated with Gomisin A at a concentration of 10 and 100 ${\mu}g$/head showed a significant reduction in tumor-induced angiogenesis of $151{\pm}16.9%$ and $98.5{\pm}29.5%$, respectively. Furthermore, tumor metastasis analysis revealed that the administration of Gomisin A at a concentration of 10 and 100 ${\mu}g$/head inhibited tumor metastasis by $13.5{\pm}8.56%$ and $58.3{\pm}9.12%$, respectively. In addition, Gomisin A significantly decreased cell adhesion of the B16BL6 cells to the extracellular matrix. These results demonstrate that Gomisin A inhibits tumor growth via suppression of angiogenesis and tumor metastasis inhibition, without cellular toxicity. The pharmacological efficacy of Gomisin A suggests that it may be a potential candidate for the development of cancer drugs.

Thymic Neuroendocrine Tumor (흉선의 신경내분비 종양)

  • 이응배;이상철;박태인;조준용;장봉현;이종태;김규태
    • Journal of Chest Surgery
    • /
    • v.35 no.4
    • /
    • pp.325-328
    • /
    • 2002
  • The neuroendocrine tumor is a rare thymic neoplasm, which has been regarded as a distinct tumor from thymoma and originates from Kultschizky cell. The pathologic diagnosis of thymic neuroendocrine tumor has been on findings from light microscopy, immunohistochemical studies, and electron microscopy. About 50% of thymic carcinoids are seen with endocrinopathies. Recurrence and extrathoracic metastasis are characteristics of thymic carcinoids. Surgical removal of the initial and recurred tumor is considered to be the most effective treatment. The role of the adjuvant chemotherapy and radiotherapy is still uncertain. Herein we report a case of thymic neuroendocrine tumor, which was resected surgically.

Image-Based Assessment and Clinical Significance of Absorbed Radiation Dose to Tumor in Repeated High-Dose $^{131}I$ Anti-CD20 Monoclonal Antibody (Rituximab) Radioimmunotherapy for Non-Hodgkin's Lymphoma (반복적인 $^{131}I$ rituximab 방사면역치료를 시행 받은 비호지킨 림프종 환자 군에서 종양 부위의 영상기반 방사선 흡수선량 평가와 임상적 의의)

  • Byun, Byung-Hyun;Kim, Kyeong-Min;Woo, Sang-Keun;Choi, Tae-Hyun;Kang, Hye-Jin;Oh, Dong-Hyun;Kim, Byeong-Il;Cheon, Gi-Jeong;Choi, Chang-Woon;Lim, Sang-Moo
    • Nuclear Medicine and Molecular Imaging
    • /
    • v.43 no.1
    • /
    • pp.60-71
    • /
    • 2009
  • Purpose: We assessed the absorbed dose to the tumor ($Dose_{tumor}$) by using pretreatment FDG-PET and whole-body (WB) planar images in repeated radioimmunotherapy (RIT) with $^{131}I$ rituximab for NHL. Materials and Methods: Patients with NHL (n=4) were administered a therapeutic dose of $^{131}I$ rituximab. Serial WB planar images alter RIT were acquired and overlaid to the coronal maximum intensity projection (MIP) PET image before RIT. On registered MIP PET and WB planar images, 2D-ROls were drawn on the region of tumor (n=7) and left medial thigh as background, and $Dose_{tumor}$ was calculated. The correlation between $Dose_{tumor}$ and the CT-based tumor volume change alter RIT was analyzed. The differences of $Dose_{tumor}$ and the tumor volume change according to the number of RIT were also assessed. Results: The values of absorbed dose were $397.7{\pm}646.2cGy$ ($53.0{\sim}2853.0cGy$). The values of CT-based tumor volume were $11.3{\pm}9.1\;cc$ ($2.9{\sim}34.2cc$), and the % changes of tumor volume before and alter RIT were $-29.8{\pm}44.3%$ ($-100.0%{\sim}+42.5%$), respectively. $Dose_{tumor}$ and the tumor volume change did not show the linear relationship (p>0.05). $Dose_{tumor}$ and the tumor volume change did not correlate with the number of repeated administration (p>0.05). Conclusion: We could determine the position and contour of viable tumor by MIP PET image. And, registration of PET and gamma camera images was possible to estimate the quantitative values of absorbed dose to tumor.

A Case of Intradural Extramedullary Cord Tumor Metastasis from Adenocarcinoma of the Lung (경막내 수외 척수로 전이된 폐선암 1예)

  • Lee, Je-Kyung;Lee, Yong-Chul;Rhee, Yang-Keun
    • Tuberculosis and Respiratory Diseases
    • /
    • v.43 no.2
    • /
    • pp.262-266
    • /
    • 1996
  • Intradural extramedullary spinal metastasis from systemic tumor is extremely rare but epidural extramedullary cord tumor metastasis from the lung is relatively common. A 57 year-old male patient was admitted to department of internal medicine and neurosurgery in Chonbuk National University Hospital because of coughing, low back pain radiate to the right great toe, and numbness of the right calf area. Spinal MRI scan revealed round oval shaped mass lesion on just below the level of the conus medullaris. Authors present the clinical, histologic, radiologic features of spinal intradural metastatic tumor and operative total removal followed by chemothrapy with an extensive review of literatures.

  • PDF

Limb Salvage Surgery with Tumor Prosthesis for the Malignant Bone Tumors Involving the Proximal Femur (대퇴골 근위부 악성 골종양 환자에서 종양 대치물을 이용한 사지 구제술)

  • Chun, Young Soo;Baek, Jong Hun;Lee, Seung Hyuk;Lee, Chung Hwan;Han, Chung Soo
    • The Journal of the Korean bone and joint tumor society
    • /
    • v.20 no.1
    • /
    • pp.7-13
    • /
    • 2014
  • Purpose: As well as patient survival, the restoration of postoperative function such as ambulation is important in limb salvage operations for treatment of malignant bone tumors involving the proximal femur. The authors analyzed clinical outcomes of limb salvage operations using tumor prostheses for metastatic or primary malignant bone tumors in the proximal femur. Materials and Methods: From February 2005 to January 2014, 20 cases (19 patients) with malignant bone tumor involving the proximal femur with pain or complicated pathologic fracture were treated with segmental resection and limb salvage operations with tumor prostheses. Mean age was 63.1 years (range 35-86). Fourteen patients were male and six ones were female. The mean follow-up period was 20 months (1-94 months). There were 15 cases of metastatic bone tumor, 4 cases of osteosarcoma, and 1 case of multiple myeloma. The primary tumors of the metastatic bone tumors included 4 lung cancers, 3 hepatocellular carcinomas, and 3 renal cell carcinomas. Other primary tumors were breast cancer, thyroid cancer, colon cancer, prostate cancer, and malignant spindle cell tumor, each in 1 case. Modular tumor prostheses were used in all cases; (Kotz's$^{(R)}$ Modular Tumor prosthesis (Howmedica, Rutherford, New Jersey) in 3 cases, MUTARS$^{(R)}$ proximal femur system (Implantcast, Munster, Germany) in 17 cases). Perioperative pain was assessed with Visual Analogue Scales (VAS). Postoperative functional outcome was assessed with Musculoskeletal Tumor Society (MSTS) grading system. Results: Out of 20 cases (19 patients), 11 cases (10 patients) survived at the last follow-up. Average postoperative survival of the 9 deceased patients was 10.1 months (1-38 months). VAS score improved from pre-operative average of 8.40 (5-10) to 1.35 (0-3) after operation. Average postoperative MSTS function score was 19.65 (65.50%, 7-28). The associated complications were 2 local recurrences, 3 hematomas, 3 infections, 2 scrotal swellings, and 1 dislocation. There was no case of periprosthetic fracture or loosening. Conclusion: Limb salvage operation with tumor prosthesis is an appropriate treatment for early pain reduction and functional restoration in malignant bone tumors in the proximal femur with pain an/or complicated pathologic fractures.

Effect of Dendritic Cell Based Cancer Vaccine Using Allogeneic Tumor Cell Lysate in Melanoma Pulmonary Metastasis Model (동종 종양 세포 용해액을 이용한 수지상 세포 항암 백신의 흑색종 폐암 전이 모델에서의 효과 연구)

  • Lee, Young-Joon;Kim, Myung-Joo;In, So-Hee;Choi, Ok-Mi;Baek, So-Young;Kwon, Young-Do;Lee, Hyun-Ah
    • IMMUNE NETWORK
    • /
    • v.5 no.3
    • /
    • pp.163-171
    • /
    • 2005
  • Background: To perform the successful dendritic cell-based cancer immunotherapy one of the main issues to be solved is the source of antigen for DC pulsing. Limitations occur by using auto-tumor lysate due to the difficulties obtaining enough tumor tissue(s) quantitatively as well as qualitatively. In this study the possibility of allogeneic tumor cell lysate as a DC pulsing antigen has been tested in mouse melanoma pulmonary me tastasis model. Methods: B16F10 melanoma cells $(1{\timeS}10^5/mouse)$ were inoculated intra venously into the C57BL/6 mouse. Therapeutic DCs were cultured from the bone marrow myeloid lineage cells with GM-CSF and IL-4 (1,000 U/ml each) for 7 days and pulsed with lysate of either autologous B16F10 (B-DC), allogeneic K1735 (C3H/He origin; K-DC) or CloneM3 (DBA2 origin; C-DC) melanoma cells for 18 hrs. Pulsed-DCs $(1{\times}10^6/mouse)_{[CGP1]}$ were injected i.p. twice with one week interval starting from the day 1 after tumor cell inoculation. Results: Without observable toxicity, allogeneic tumor cell lysate pulsed-DC induced the significantly better anti-tumor response (tumor scale: $2.7{\pm}0.3,\;0.7{\pm}0.3\;and\;0.3{\pm}0.2$ for saline, B-DC and C-DC treated group, respectively). Along with increased tumor specific lymphocyte proliferations, induction of IFN-${\gamma}$ secretion against both auto- and allo-tumor cell lysates was observed from the DC treated mice. (w/B16F10-lysate: $44.97{\pm}10.31,\;1787.94{\pm}131.18,\;1257.15{\pm}48.27$, w/CloneM3 lysate: 0, $1591.13{\pm}1.83,\;1460.47{\pm}86.05pg/ml$ for saline, B-DC and C-DC treated group, respectively) Natural killer cell activity was also increased in the mice treated with tumor cell lysate pulsed-DC ($8.9{\pm}_{[CGP2]}0.1,\;11.6{\pm}0.8\;and\;12.6{\pm}0.7%$ specific NK activity for saline, B-DC and C-DC treated group, respectively). Conclusion: Conclusively, promising data were obtained that allogeneic-tumor cell lysate can be used as a tumor antigen for DC-based cancer immunotherapy.

Relation of the Activities of Plasminogen Activator and Plasmin-like Protease with Malignant Behavior of Skin Tumor of Rats (Plasminogen Activator 및 Plasmin-like Protease활성도의 변화와 쥐 피부암의 악성)

  • Yun Kee;Park, Sang C.;Doo B. Ha;Chin H. Chung
    • The Korean Journal of Zoology
    • /
    • v.31 no.3
    • /
    • pp.185-190
    • /
    • 1988
  • To investigate whether malignant behavior of skin tumor correlates with changes in the level of proteolytic activities in skin tumors, rats were treated with 7,12-dimethylbenzanthracene followed by photbor ester. Tumors induced upon the treatrnents exhibited more than 20-fold increase in the activity of plasminogen activator and about 3-fold of plasmin-like activity. as compared to those in treated controls. Furthermore, the former activity was raised to about 6-fold even in the preneoplastic dssues of the skin tissues. On the other hand, the proteolytic activity against casein and insulin decreased to several-fold in the tumor tissues while antitrvpsin activity remained similar in both tumor and controls. Thus, the increase in the activities of plasmInogen activator and plasminlike enzyme appears to occur as a charaderistic to skin cancer and may involve in invasion and metsstasis of the tumor.

  • PDF